Published in Ther Adv Musculoskelet Dis on December 01, 2011
Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J (2013) 1.41
Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res (2013) 1.16
Postmenopausal osteoporosis: the role of immune system cells. Clin Dev Immunol (2013) 1.04
Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res (2013) 0.99
A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence (2014) 0.86
Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep (2014) 0.81
Current management of aneurysmal bone cysts. Curr Rev Musculoskelet Med (2016) 0.80
Chronic kidney disease and the skeleton. Bone Res (2014) 0.79
The Role of the Osteocyte in Bone and Nonbone Disease. Endocrinol Metab Clin North Am (2016) 0.78
A simple approach for the preoperative assessment of sacral morphology for percutaneous SI screw fixation. Arch Orthop Trauma Surg (2016) 0.76
Denosumab: A bone antiresorptive drug. Med J Armed Forces India (2014) 0.76
Can denosumab be a substitute, competitor, or complement to bisphosphonates? Korean J Pain (2017) 0.75
Osteoporosis: a discussion on the past 5 years. Curr Rev Musculoskelet Med (2017) 0.75
Osteoclast differentiation and activation. Nature (2003) 18.59
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
The amazing osteocyte. J Bone Miner Res (2011) 5.32
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 3.17
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab (2008) 2.43
Denosumab and bisphosphonates: different mechanisms of action and effects. Bone (2010) 2.37
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res (2010) 2.20
Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem (2008) 1.88
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74
Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res (2008) 1.70
Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord (2010) 1.64
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab (2011) 1.59
The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res (2001) 1.57
Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res (2011) 1.40
Bone remodeling, energy metabolism, and the molecular clock. Cell Metab (2008) 1.39
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int (2012) 1.29
Phosphate and FGF-23. Kidney Int Suppl (2011) 1.19
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res (2011) 1.19
Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading. Curr Osteoporos Rep (2011) 1.13
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab (2010) 1.12
Osteoblasts: novel roles in orchestration of skeletal architecture. Int J Biochem Cell Biol (2003) 1.10
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int (2010) 0.98
The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol (2009) 0.96
PTH battles TGF-beta in bone. Nat Cell Biol (2010) 0.84
Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med (2009) 0.80
Sclerostin. J Osteoporos (2010) 0.78
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93
Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res (2004) 3.37
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin (2008) 1.79
Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res (2004) 1.76
National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom (2008) 1.76
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74
Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol (2004) 1.68
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 1.66
White-rot fungi demonstrate first biodegradation of phenolic resin. Environ Sci Technol (2006) 1.64
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab (2011) 1.59
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res (2011) 1.40
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab (2012) 1.24
Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception (2006) 1.21
Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom (2004) 1.18
Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther (2004) 1.17
A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res (2011) 1.14
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.12
Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res (2007) 1.12
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Secondary and tertiary hyperparathyroidism. J Clin Densitom (2012) 1.07
It's hard to be a real doctor now. Pharos Alpha Omega Alpha Honor Med Soc (2015) 1.07
Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. J Clin Densitom (2006) 1.04
Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res (2009) 1.04
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective. J Bone Miner Res (2012) 1.03
Safety of bisphosphonates in the treatment of osteoporosis. Am J Med (2009) 1.02
Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res (2004) 1.00
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin (2005) 0.98
Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep (2012) 0.95
Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001. J Clin Densitom (2002) 0.95
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res (2009) 0.94
Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res (2014) 0.91
More bone density testing is needed, not less. J Bone Miner Res (2012) 0.91
Standards for performing DXA in individuals with secondary causes of osteoporosis. J Clin Densitom (2006) 0.91
Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. J Clin Densitom (2013) 0.90
Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom (2008) 0.88
RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res (2014) 0.85
Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int (2010) 0.85
Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf (2007) 0.85
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab (2015) 0.84
Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom (2011) 0.84
2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. J Clin Densitom (2013) 0.83
DXA-generated Z-scores and T-scores may differ substantially and significantly in young adults. J Clin Densitom (2007) 0.83
Osteoporosis update from the 2012 Santa Fe Bone Symposium. J Clin Densitom (2013) 0.82
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. Bone (2008) 0.82
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int (2005) 0.82
Use of lowest single lumbar spine vertebra bone mineral density T-score and other T-score approaches for diagnosing osteoporosis and relationships with vertebral fracture status. J Clin Densitom (2008) 0.82
Uses and misuses of quantitative ultrasonography in managing osteoporosis. Cleve Clin J Med (2006) 0.82
Dual-energy X-ray absorptiometry diagnostic discordance between Z-scores and T-scores in young adults. J Clin Densitom (2009) 0.81
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol (2005) 0.81
What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis? J Clin Densitom (2002) 0.81
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. N Engl J Med (2004) 0.80
Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A. Kanis et al. J Clin Densitom (2005) 0.80
2008 Santa Fe Bone Symposium: update on osteoporosis. J Clin Densitom (2009) 0.79
Bone density testing: science, the media, and patient care. Curr Osteoporos Rep (2014) 0.78
The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. J Clin Densitom (2010) 0.78
Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. J Bone Miner Res (2009) 0.78
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. Endocr Pract (2016) 0.77
Diagnostic agreement at the total hip using different DXA systems and the NHANES III database. J Clin Densitom (2007) 0.77
Editorial: greater risk, greater benefit--true or false? J Clin Endocrinol Metab (2003) 0.77
Update on osteoporosis from the 2014 Santa Fe Bone symposium. Endocr Res (2015) 0.77
Bone-density testing interval and transition to osteoporosis. N Engl J Med (2012) 0.77
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. Endocr Pract (2016) 0.77
All bisphosphonates are (or may not be) the same: potential reasons for clinical differences. J Womens Health (Larchmt) (2010) 0.76
FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. J Clin Densitom (2011) 0.76
Osteoporosis update from the 2010 santa fe bone symposium. J Clin Densitom (2011) 0.76
Determinants of bone strength. J Bone Miner Res (2003) 0.75
Fragility fractures in chronic kidney disease: A clarification of views (December 2009). Cleve Clin J Med (2010) 0.75
Letter to the editor. Bone (2004) 0.75
Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007. J Clin Densitom (2008) 0.75
Proceedings of the 2011 Santa Fe Bone symposium. J Clin Densitom (2012) 0.75
New or worsening lumbar spine vertebral fractures increase lumbar spine bone mineral density and falsely suggest improved skeletal status. J Clin Densitom (2006) 0.75
2009 Santa Fe Bone symposium. J Clin Densitom (2010) 0.75
Skeletal health and bone strength: DXA and beyond growth for the Journal of Clinical Densitometry. J Clin Densitom (2008) 0.75
In Memoriam: Sergio Ragi-Eis, MD, CCD, CDT (April 8, 1962–February 22, 2012). J Clin Densitom (2012) 0.75
Position Development Conference. South Med J (2003) 0.75
Upper tract surveillance in primary bladder cancer follow-up. BJU Int (2004) 0.75
Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women. Menopause (2016) 0.75